Claims for Patent: 11,241,425
✉ Email this page to a colleague
Summary for Patent: 11,241,425
Title: | Composition for treating mental illness |
Abstract: | The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use. The present invention provides methods of reducing antipsychotic induced weight gain, methods for suppressing food intake and reducing ghrelin levels induced by atypical antipsychotic medications in a patient. |
Inventor(s): | Deaver; Daniel R. (Wilmington, NC), Todtenkopf; Mark (Franklin, MA) |
Assignee: | Alkermes Pharma Ireland Limited (Dublin, IE) |
Application Number: | 17/071,236 |
Patent Claims: |
1. A method of reducing induced weight gain associated with olanzapine administration in a patient suffering from bipolar disorder and in need of olanzapine treatment,
comprising orally administering, daily, to the patient a pharmaceutical composition comprising: olanzapine; 10 mg of a compound, based on the free base weight and having the structure: ##STR00022## or a pharmaceutically acceptable salt thereof; and a
pharmaceutically acceptable excipient.
2. The method according to claim 1, wherein the compound is present in the pharmaceutical composition as a pharmaceutically acceptable salt. 3. The method according to claim 1, wherein the pharmaceutical composition is a tablet. 4. The method according to claim 1, wherein the pharmaceutical composition further comprises lactose. 5. The method according to claim 1, wherein the pharmaceutical composition further comprises magnesium stearate. 6. The method according to claim 5, wherein the pharmaceutical composition further comprises lactose. 7. The method according to claim 1, wherein the bipolar disorder is bipolar disorder I. 8. The method according to claim 1, wherein the bipolar disorder is bipolar disorder I with a mixed or manic episode. 9. A method of reducing induced weight gain associated with olanzapine administration in a patient suffering from a manic or mixed episode associated with bipolar disorder I and in need of olanzapine treatment, comprising orally administering, daily, to the patient a pharmaceutical composition comprising: olanzapine; 10 mg of a compound, based on the free base weight, having the structure: ##STR00023## and a pharmaceutically acceptable excipient; wherein the compound is present in the pharmaceutical composition as a pharmaceutically acceptable salt. 10. The method according to claim 9, wherein the pharmaceutical composition is a tablet. 11. A method of reducing induced weight gain associated with olanzapine administration in a patient suffering from bipolar disorder and in need of olanzapine treatment, comprising: orally administering daily to the patient 10 mg, based on the free base weight, a compound having the structure: ##STR00024## or a pharmaceutically acceptable salt thereof; and administering to the patient, daily, an antipsychotic, wherein the antipsychotic is olanzapine. 12. The method according to claim 11, wherein the compound is present as a pharmaceutically acceptable salt. 13. The method according to claim 11, wherein administering the compound and administering the olanzapine occurs concurrently. 14. The method according to claim 11, wherein the bipolar disorder is bipolar disorder I. 15. A method of reducing induced weight gain associated with olanzapine administration in a patient suffering from a manic or mixed episode associated with bipolar disorder I and in need of olanzapine treatment, comprising: orally administering daily to the patient 10 mg, based on the free base weight, a compound having the structure: ##STR00025## or a pharmaceutically acceptable salt thereof; and administering to the patient, daily, an antipsychotic, wherein the antipsychotic is olanzapine. 16. The method according to claim 15, wherein the compound is present as a pharmaceutically acceptable salt. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.